Brokerages Expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) to Announce -$0.20 Earnings Per Share

Analysts expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) to post ($0.20) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Allena Pharmaceuticals’ earnings. Allena Pharmaceuticals reported earnings of ($0.21) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.8%. The company is expected to issue its next earnings results on Monday, January 1st.

Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Allena Pharmaceuticals.

Allena Pharmaceuticals (NASDAQ:ALNA – Get Rating) last posted its earnings results on Thursday, March 31st. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05.

A number of equities research analysts have commented on ALNA shares. HC Wainwright reissued a “neutral” rating on shares of Allena Pharmaceuticals in a research note on Monday, March 21st. B. Riley cut Allena Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Tuesday, March 22nd. LADENBURG THALM/SH SH reissued a “neutral” rating on shares of Allena Pharmaceuticals in a research note on Monday, March 21st. Finally, Zacks Investment Research raised Allena Pharmaceuticals from a “sell” rating to a “hold” rating and set a $0.25 price objective for the company in a research note on Wednesday, March 23rd.

NASDAQ ALNA traded up $0.01 during trading hours on Thursday, hitting $0.22. 22,223 shares of the company’s stock were exchanged, compared to its average volume of 2,305,657. The stock has a 50-day simple moving average of $0.36 and a 200 day simple moving average of $0.57. Allena Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $1.45. The firm has a market cap of $18.33 million, a price-to-earnings ratio of -0.26 and a beta of 1.92.

A number of institutional investors have recently modified their holdings of the stock. Altium Capital Management LP bought a new stake in Allena Pharmaceuticals during the third quarter worth $963,000. Morgan Stanley raised its stake in shares of Allena Pharmaceuticals by 63.9% in the second quarter. Morgan Stanley now owns 1,045,481 shares of the company’s stock valued at $1,359,000 after buying an additional 407,599 shares during the period. Geode Capital Management LLC raised its stake in shares of Allena Pharmaceuticals by 15.8% in the third quarter. Geode Capital Management LLC now owns 330,599 shares of the company’s stock valued at $298,000 after buying an additional 45,032 shares during the period. Millennium Management LLC raised its stake in shares of Allena Pharmaceuticals by 75.5% in the second quarter. Millennium Management LLC now owns 187,431 shares of the company’s stock valued at $244,000 after buying an additional 80,625 shares during the period. Finally, Kestra Advisory Services LLC raised its stake in shares of Allena Pharmaceuticals by 53.8% in the fourth quarter. Kestra Advisory Services LLC now owns 161,500 shares of the company’s stock valued at $96,000 after buying an additional 56,500 shares during the period. Institutional investors and hedge funds own 24.20% of the company’s stock.

About Allena Pharmaceuticals (Get Rating)

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Stories